$ACUT
Accustem Sciences Inc.

2024 Q1 Form 10-K Financial Statement

#000149315224010938 Filed on March 22, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $502.5K $155.6K $1.907M
YoY Change -38.48% -81.57% -45.13%
% of Gross Profit
Research & Development $23.20K $89.54K $139.7K
YoY Change 48.68% -32.74% -47.68%
% of Gross Profit
Depreciation & Amortization $908.00 $910.00 $3.630K
YoY Change 0.0% 0.0% 9.3%
% of Gross Profit
Operating Expenses $526.6K $246.0K $2.051M
YoY Change -36.81% -74.86% -45.26%
Operating Profit -$526.6K -$2.051M
YoY Change -36.81% -45.26%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$526.6K -$246.0K -$2.051M
YoY Change -36.81% -74.86% -45.26%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$526.6K -$246.0K -$2.051M
YoY Change -36.81% -74.86% -45.26%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.18
Diluted Earnings Per Share -$0.05 -$0.02 -$0.18
COMMON SHARES
Basic Shares Outstanding 11.35M shares 11.35M shares 11.35M shares
Diluted Shares Outstanding 11.35M shares 11.35M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.370K $21.48K $21.48K
YoY Change -94.81% -97.07% -97.07%
Cash & Equivalents $9.373K $21.48K $21.48K
Short-Term Investments
Other Short-Term Assets $38.43K $108.4K
YoY Change -45.28%
Inventory
Prepaid Expenses $38.43K $108.4K
Receivables
Other Receivables
Total Short-Term Assets $47.80K $129.8K $129.9K
YoY Change -80.15% -86.07% -86.07%
LONG-TERM ASSETS
Property, Plant & Equipment $3.140K $4.048K $4.050K
YoY Change -53.62% -47.28% -47.27%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $3.140K $4.048K $4.050K
YoY Change -53.62% -47.28% -47.27%
TOTAL ASSETS
Total Short-Term Assets $47.80K $129.8K $129.9K
Total Long-Term Assets $3.140K $4.048K $4.050K
Total Assets $50.94K $133.9K $133.9K
YoY Change -79.42% -85.75% -85.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $649.5K $578.4K $578.4K
YoY Change 111.51% 85.48% 85.48%
Accrued Expenses $219.6K $156.4K $156.4K
YoY Change -69.67% -69.84% -69.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $55.68K $55.68K
YoY Change -47.74% -47.74%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.671M $2.245M $2.245M
YoY Change 123.65% 108.06% 108.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.671M $2.245M $2.245M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.671M $2.245M $2.245M
YoY Change 123.65% 108.06% 108.06%
SHAREHOLDERS EQUITY
Retained Earnings -$7.049M -$6.522M
YoY Change 32.88% 45.86%
Common Stock $11.35K $11.35K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$2.620M -$2.112M -$2.112M
YoY Change
Total Liabilities & Shareholders Equity $50.94K $133.9K $133.9K
YoY Change -79.42% -85.75% -85.75%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$526.6K -$246.0K -$2.051M
YoY Change -36.81% -74.86% -45.26%
Depreciation, Depletion And Amortization $908.00 $910.00 $3.630K
YoY Change 0.0% 0.0% 9.3%
Cash From Operating Activities -$237.4K -$295.0K -$1.616M
YoY Change -46.79% -39.88% -10.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $225.2K 245.5K $903.1K
YoY Change -310.01% -328.91% -64.6%
NET CHANGE
Cash From Operating Activities -$237.4K -295.0K -$1.616M
Cash From Investing Activities 0.000
Cash From Financing Activities $225.2K 245.5K $903.1K
Net Change In Cash -$12.11K -49.52K -$712.5K
YoY Change -97.81% -91.72% -197.07%
FREE CASH FLOW
Cash From Operating Activities -$237.4K -$295.0K -$1.616M
Capital Expenditures $0.00
Free Cash Flow -$295.0K -$1.616M
YoY Change -39.88% -11.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001850767
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
CY2023 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
usd
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
usd
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2022 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
usd
CY2023 ACUT Proceeds From Receipt Of Subscription Receivable
ProceedsFromReceiptOfSubscriptionReceivable
usd
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
usd
CY2022 ACUT Amendment Of Issuance Of Note Payable For Payment Of Prepaid Expense
AmendmentOfIssuanceOfNotePayableForPaymentOfPrepaidExpense
usd
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
pure
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
pure
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
usd
CY2023 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
usd
CY2023 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
usd
CY2023 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
usd
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
usd
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
usd
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Security12b Title
Security12bTitle
Common Stock
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
15998614 usd
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
11346535 shares
CY2023 dei Auditor Firm
AuditorFirmId
339
CY2023 dei Auditor Name
AuditorName
Mazars USA LLP
CY2023 dei Auditor Location
AuditorLocation
New York, NY
CY2023Q4 us-gaap Cash
Cash
21481 usd
CY2022Q4 us-gaap Cash
Cash
733978 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
108368 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
168430 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
29603 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129849 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
932011 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7678 usd
CY2023Q4 us-gaap Assets
Assets
133897 usd
CY2022Q4 us-gaap Assets
Assets
939689 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
578378 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
311834 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1454986 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
142229 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
518625 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
55679 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
106551 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2245477 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1079239 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2245477 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1079239 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11346535 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11346535 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11346535 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
11346535 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
11346 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
11346 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4399019 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
4320385 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6521945 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4471281 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
133897 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
939689 usd
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
139663 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
266933 usd
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1911001 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3479486 usd
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2050664 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2050664 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3746419 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.34
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.34
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11346535 shares
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11346535 shares
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11016165 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11016165 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
650673 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
133889 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2675940 usd
CY2022 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
204879 usd
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8469 usd
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-66981 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3746419 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-139550 usd
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
78634 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2050664 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2111580 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2050664 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3746419 usd
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
66981 usd
CY2023 us-gaap Depreciation
Depreciation
3630 usd
CY2022 us-gaap Depreciation
Depreciation
3321 usd
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
78634 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
133889 usd
CY2022 us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-1353373 usd
CY2023 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-343122 usd
CY2022 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-270692 usd
CY2023 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-29603 usd
CY2022 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
29603 usd
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
266544 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-76846 usd
CY2023 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
66000 usd
CY2022 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-48609 usd
CY2023 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-352512 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
401130 usd
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1615643 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1806053 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10999 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10999 usd
CY2023 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
1246757 usd
CY2022 ACUT Proceeds From Receipt Of Subscription Receivable
ProceedsFromReceiptOfSubscriptionReceivable
204879 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2675940 usd
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
8469 usd
CY2023 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
343611 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
338258 usd
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
903146 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2551030 usd
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-712497 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
733978 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
733978 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21481 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
733978 usd
CY2023 us-gaap Notes Issued1
NotesIssued1
372879 usd
CY2022 us-gaap Notes Issued1
NotesIssued1
439122 usd
CY2023 ACUT Amendment Of Issuance Of Note Payable For Payment Of Prepaid Expense
AmendmentOfIssuanceOfNotePayableForPaymentOfPrepaidExpense
-89818 usd
CY2023 us-gaap Interest Paid Net
InterestPaidNet
7192 usd
CY2022 us-gaap Interest Paid Net
InterestPaidNet
7474 usd
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2050664 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6521945 usd
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_845_eus-gaap--UseOfEstimates_zzgR0KcygKqj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_868_z3QV6cDWhiC9">Use of Estimates</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S GAAP requires management of the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10999 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6951 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3321 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4048 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7678 usd
CY2023 us-gaap Depreciation
Depreciation
3630 usd
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
369528 usd
CY2023Q4 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
146594 usd
CY2022Q4 ACUT Accrued Legal Expenses Current
AccruedLegalExpensesCurrent
124245 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9840 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
24852 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
156434 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
518625 usd
CY2023Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
30822 usd
CY2022Q2 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
35751 usd
CY2023 us-gaap Foreign Currency Translation Adjustment Description
ForeignCurrencyTranslationAdjustmentDescription
converted from EUROS to USD using exchange rate of €1:$1.0675
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-2050664 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-3746419 usd
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1611115 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1710115 shares
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1611115 shares
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1710115 shares
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76634 usd
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
133889 usd
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0154 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.572 pure
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.657 pure
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
772580 usd
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
872662 usd
CY2023Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0 shares
CY2023 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.2100 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
0.2100 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0081 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.0096 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0000 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0256 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2358 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.1884 pure
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0339 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0136 pure
CY2023 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0000 pure
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1230980 usd
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
731909 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
88423 usd
CY2023Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
293 usd
CY2022Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
252 usd
CY2023Q4 ACUT Deferred Tax Assets Patents
DeferredTaxAssetsPatents
26588 usd
CY2022Q4 ACUT Deferred Tax Assets Patents
DeferredTaxAssetsPatents
25998 usd
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
101024 usd
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
28793 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1358885 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
875375 usd
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1358885 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
875375 usd
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1358885 usd
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
875375 usd

Files In Submission

Name View Source Status
0001493152-24-010938-index-headers.html Edgar Link pending
0001493152-24-010938-index.html Edgar Link pending
0001493152-24-010938.txt Edgar Link pending
0001493152-24-010938-xbrl.zip Edgar Link pending
acut-20231231.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
ex4-4.htm Edgar Link pending
ex97-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
acut-20231231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
acut-20231231_cal.xml Edgar Link unprocessable
acut-20231231_lab.xml Edgar Link unprocessable
acut-20231231_pre.xml Edgar Link unprocessable